Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492322 · ClinicalTrials.gov registry record
SPECT Imaging of DAT Genotype
A clinical trial, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- 14
- Enrollment target
NCT01492322: Clinical Trial study, sponsored by University of Pennsylvania.
NCT01492322 is a clinical trial that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01492322 was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
A polymorphism in the dopamine transporter (DAT) may determine how much dopamine is available at the synapse and this may affect the underlying reasons for relapse in smokers. This research will use Single-photon emission computed tomography SPECT and the DAT-specific ligand, TRODAT (Dopamine Transporter Density by \[99mTc\]), to examine the availability of DAT in smokers grouped by genotype in the sated (just having smoked) and withdrawal (4 hours without smoking) conditions.
Interventions
- RADIATION TRODAT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01492322
The ClinicalTrials.gov registry entry for NCT01492322 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRODAT is the first listed.
NCT01492322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01492322 about?
NCT01492322 is a clinical study titled "SPECT Imaging of DAT Genotype". A polymorphism in the dopamine transporter (DAT) may determine how much dopamine is available at the synapse and this may affect the underlying reasons for relapse in smokers. This research will use Single-photon emission computed tomography SPECT and the DAT-specific ligand, TRODAT (Dopamine Transp...
What is the current status of trial NCT01492322?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2011-11. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01492322?
The interventions under investigation include: TRODAT (RADIATION).
Who is sponsoring clinical trial NCT01492322?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.